ArticleFrontiers in microbiology2022
Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Article
- Targeting MCR-3 and membrane biosynthesis: mechanistic insights into pterostilbene-colistin synergy.Microbiology spectrum · 2026Article
- Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment ofFrontiers in cellular and infection microbiology · 2025Article
- Metabolomics unveil key pathways underlying the synergistic activities of aztreonam and avibactam against multidrug-resistant Escherichia coli.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Article
- Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-ProducingPharmaceutics · 2023Article
- Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment ofFrontiers in cellular and infection microbiology · 2023Article
- Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination againstFrontiers in microbiology · 2023Article
- The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistantFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Empirical therapies using polymyxins combined with other antibiotics are recommended in the treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.